FIELD: biotechnology.
SUBSTANCE: invention refers to medicine and biotechnology, particularly to determining the proliferative activity of tumor cells of triple-negative breast cancer. Method involves preparation of paraffin blocks from tumor tissue and histological sections, their dewaxing in hexane. Uncoloured dewaxed histological sections of tumor tissue are subjected to fluorimetric analysis and fluorescence excitation spectra are measured from 230 to 360 nm at a detection wavelength of 410 nm and fluorescence spectra at excitation wavelength of 300 nm and detection wavelength from 330 to 450 nm, determining the ratio between intensities of curves with maxima in region of 265 and 305 nm (I265/I305), and if I265/I305 = 1.0, the proliferative activity is low, the ratio I265/I305 indicates high proliferative activity.
EFFECT: invention increases efficiency of obtained results.
1 cl, 3 dwg, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETECTING THE PRESENCE OF ESTROGEN AND PROGESTERONE RECEPTORS IN TISSUE OF HER2-NEGATIVE BREAST CANCER | 2018 |
|
RU2691606C1 |
METHOD FOR DIFFERENTIAL DIAGNOSTICS OF ADENOMA WITH III DEGREE DYSPLASIA AND EARLY COLON ADENOCARCINOMA | 2016 |
|
RU2638805C1 |
METHOD FOR PREDICTION OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS SUFFERING TRIPLE-NEGATIVE RESECTABLE BREAST CANCER | 2014 |
|
RU2560707C1 |
METHOD FOR PREDICTING THE COURSE OF A PATHOLOGICAL PROCESS IN LUMINAL NON-HYPEREXPRESSION OF Her2Neu PRIMARY OPERABLE BREAST CANCER IN POSTMENOPAUSAL WOMEN | 2018 |
|
RU2694843C1 |
METHOD OF PREDICTING EFFICIENCY OF NEOADJUVANT CHEMICAL THERAPY IN PATIENTS WITH RESECTABLE BASAL-LIKE TRIPLE-NEGATIVE BREAST CANCER | 2013 |
|
RU2538638C1 |
METHOD FOR FORECAST OF BREAST CANCER | 2017 |
|
RU2664671C1 |
METHOD OF PREDICTING RESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2802671C1 |
METHOD OF PREDICTING ACHIEVEMENT OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER, WHO OBTAINED CHEMOTHERAPY COURSES IN CAX REGIMEN | 2014 |
|
RU2563180C1 |
METHOD FOR DETECTING EFFICIENCY OF ANTI-TUMOR THERAPY OF SKIN MELANOMAS | 2004 |
|
RU2280483C2 |
METHOD OF CHOOSING A THERAPEUTIC APPROACH TO PATIENTS WITH REGIONAL LYMPHADENOPATHY OF UNKNOWN ORIGIN IN GASTRIC ADENOCARCINOMA | 2020 |
|
RU2740145C1 |
Authors
Dates
2019-06-25—Published
2018-06-08—Filed